Verona Pharma (VRNA) Competitors

-0.36 (-2.69%)
(As of 05/17/2024 ET)


Should you be buying Verona Pharma stock or one of its competitors? The main competitors of Verona Pharma include Collegium Pharmaceutical (COLL), Prothena (PRTA), Enliven Therapeutics (ELVN), AbCellera Biologics (ABCL), Ironwood Pharmaceuticals (IRWD), Mirum Pharmaceuticals (MIRM), Innoviva (INVA), Cassava Sciences (SAVA), Tyra Biosciences (TYRA), and Belite Bio (BLTE). These companies are all part of the "pharmaceutical preparations" industry.

Verona Pharma vs.

Collegium Pharmaceutical (NASDAQ:COLL) and Verona Pharma (NASDAQ:VRNA) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, dividends, media sentiment, profitability, analyst recommendations, community ranking, institutional ownership and risk.

85.9% of Verona Pharma shares are held by institutional investors. 4.0% of Collegium Pharmaceutical shares are held by insiders. Comparatively, 4.8% of Verona Pharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Collegium Pharmaceutical presently has a consensus target price of $39.00, indicating a potential upside of 20.11%. Verona Pharma has a consensus target price of $33.20, indicating a potential upside of 155.38%. Given Collegium Pharmaceutical's stronger consensus rating and higher possible upside, analysts clearly believe Verona Pharma is more favorable than Collegium Pharmaceutical.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Collegium Pharmaceutical
0 Sell rating(s)
4 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
Verona Pharma
0 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)

Collegium Pharmaceutical has a beta of 1.06, indicating that its stock price is 6% more volatile than the S&P 500. Comparatively, Verona Pharma has a beta of 0.43, indicating that its stock price is 57% less volatile than the S&P 500.

Collegium Pharmaceutical has a net margin of 16.46% compared to Collegium Pharmaceutical's net margin of 0.00%. Verona Pharma's return on equity of 104.98% beat Collegium Pharmaceutical's return on equity.

Company Net Margins Return on Equity Return on Assets
Collegium Pharmaceutical16.46% 104.98% 18.00%
Verona Pharma N/A -25.09%-21.24%

Collegium Pharmaceutical received 65 more outperform votes than Verona Pharma when rated by MarketBeat users. However, 79.95% of users gave Verona Pharma an outperform vote while only 65.16% of users gave Collegium Pharmaceutical an outperform vote.

Collegium PharmaceuticalOutperform Votes
Underperform Votes
Verona PharmaOutperform Votes
Underperform Votes

Collegium Pharmaceutical has higher revenue and earnings than Verona Pharma. Verona Pharma is trading at a lower price-to-earnings ratio than Collegium Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Collegium Pharmaceutical$566.77M1.87$48.15M$2.4013.53
Verona Pharma$460K2,284.04-$54.37M-$0.77-16.88

In the previous week, Collegium Pharmaceutical had 1 more articles in the media than Verona Pharma. MarketBeat recorded 12 mentions for Collegium Pharmaceutical and 11 mentions for Verona Pharma. Verona Pharma's average media sentiment score of 0.38 beat Collegium Pharmaceutical's score of 0.13 indicating that Collegium Pharmaceutical is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Collegium Pharmaceutical
5 Very Positive mention(s)
2 Positive mention(s)
2 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Verona Pharma
4 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)


Collegium Pharmaceutical beats Verona Pharma on 11 of the 18 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VRNA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

VRNA vs. The Competition

MetricVerona PharmaPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$1.05B$6.80B$5.24B$7.99B
Dividend YieldN/A2.72%44.24%3.91%
P/E Ratio-16.8810.51103.2115.05
Price / Sales2,284.04289.142,370.1481.39
Price / CashN/A34.4236.7931.98
Price / Book4.685.795.494.64
Net Income-$54.37M$138.82M$105.95M$217.28M
7 Day Performance-12.46%1.45%1.42%2.90%
1 Month Performance-17.30%4.81%4.96%6.66%
1 Year Performance-34.64%-3.83%7.84%9.89%

Verona Pharma Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
Collegium Pharmaceutical
3.0861 of 5 stars
+44.1%$1.09B$566.92M13.87197Insider Selling
1.7566 of 5 stars
-69.4%$1.11B$91.37M-6.36173Gap Up
Enliven Therapeutics
1.8682 of 5 stars
+14.9%$1.12BN/A-10.9046Analyst Revision
News Coverage
AbCellera Biologics
1.6861 of 5 stars
Ironwood Pharmaceuticals
4.4475 of 5 stars
-36.6%$1.04B$413.55M-0.98267Short Interest ↓
News Coverage
Mirum Pharmaceuticals
4.5335 of 5 stars
1.4871 of 5 stars
N/A+21.1%$1.02B$310.46M7.26112News Coverage
Positive News
Cassava Sciences
3.1541 of 5 stars
+31.4%$1.01BN/A-10.7529Analyst Forecast
Gap Up
High Trading Volume
Tyra Biosciences
1.4516 of 5 stars
+37.6%$976.19MN/A-11.0649News Coverage
Belite Bio
0.872 of 5 stars
+95.9%$1.22BN/A-33.8720Analyst Forecast
Analyst Revision
News Coverage

Related Companies and Tools

This page (NASDAQ:VRNA) was last updated on 5/19/2024 by Staff

From Our Partners